参考文献/References:
［1］ Thrumurthy SG, Chaudry MA, Hochhauser D, et al. The diagnosis and management of gastric cancer［J］. BMJ, 2013, 347: f6367.
［2］ Sun WJ, Zhou X, Zheng JH, et al. Histone acetyltransferases and deacetylases: molecular and clinical implications to gastroin testinal carcinogenesis［J］. Acta Biochim Biophys Sin (Shanghai), 2012, 44: 80 91.
［3］ Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights［J］. Pharmacol Ther, 2014, 143: 323 336.
［4］ Ververis K, Hiong A, Karagiannis TC, et al. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents［J］. Biologics, 2013, 7: 47 60.
［5］ Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as anti neoplastic agents［J］. Cancer Lett, 2009, 280: 192 200.
［6］ 刘 瑾， 任亚蝉， 吴智群． 组蛋白去乙酰化酶抑制剂MS 275在体外抑制胃癌细胞的实验研究［J］． 中国癌症杂志， 2011， 21： 585 588．
［7］ Zhang Y, Adachi M, Zhao X, et al. Histone deacetylase inhibitors FK228, N (2 aminophenyl) 4 ［N (pyridin 3 yl metho xycarbonyl)amino methyl］ benzamide and m carboxycinnamic acid bis hydroxamide augment radiation induced cell death in gastrointe stinal adenocarcinoma cells［J］. Int J Cancer, 2004, 110: 301 308.
［8］ Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights［J］. Pharmacol Ther, 2014, 143: 323 336.
［9］ Hess Stumpp H, Bracker TU, Henderson D, et al. MS 275, a potent orally available inhibitor of histone deacetylases: the development of an anticancer agent［J］. Int J Biochem Cell Biol, 2007, 39: 1388 1405.
［10］ Baradari V, H?觟pfner M, Huether A, et al. Histone deacetylase inhibitor MS 275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangio carcinoma cells［J］. World J Gastroenterol, 2007, 13: 4458 4466.
［11］ Larsson C. Epigenetic aspects on therapy development for gastroenteropancreatic neuroendocrine tumors［J］. Neuroendocri nology, 2013, 97: 19 25.
［12］ Meng J, Zhang HH, Zhou CX, et al. The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53 dependent and independent pathways［J］. Oncol Rep, 2012, 28: 384 388.
［13］ Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS 275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1［J］. Cancer Res, 2003, 63: 3637 3645.
［14］ Bonelli P, Tuccillo FM, Borrelli A, et al. CDK/CCN and CDKI alterations for cancer prognosis and therapeutic predictivity［J］. Biomed Res Int, 2014: 361020.
［15］ Mani S, Wang CG, Wu KM, et al. Cyclin dependent kinase inhibitors: novel anticancer agents［J］. Expert Opin Investig Drugs, 2000, 9: 1849 1870.
［16］ Zhou Q, Dalgard CL, Wynder C, et al. Histone deacetylase inhibitors SAHA and sodium butyrate block G1 to S cell cycle progression in neurosphere formation by adult subventricular cells［J］. BMC Neurosci, 2011, 12: 50.
［17］吴伟琪， 施 敏， 王玉刚， 等． 曲古霉素A对人胃癌细胞的抑制作用及其机制探讨［J］． 胃肠病学， 2013， 18： 143 148．